(Q36251995)

English

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial (English)

1 reference

Europe PubMed Central

13 August 2017

phase II clinical trial

0 references

organ transplantation

1 reference

based on heuristic

inferred from title

lymphoproliferative disorders

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Nancy L Bartlett

3

object named as

Nancy Bartlett

1 reference

Europe PubMed Central

13 August 2017

author name string

Anne H Blaes

1

1 reference

Europe PubMed Central

13 August 2017

Bruce A Peterson

2

1 reference

Europe PubMed Central

13 August 2017

David L Dunn

4

1 reference

Europe PubMed Central

13 August 2017

Vicki A Morrison

5

1 reference

Europe PubMed Central

13 August 2017

language of work or name

0 references

publication date

1 October 2005

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

104

1 reference

Europe PubMed Central

13 August 2017

8

1 reference

Europe PubMed Central

13 August 2017

1661-1667

1 reference

Europe PubMed Central

13 August 2017

Diagnosis and treatment of transplant-related lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical characteristics of post-transplant lymphoproliferative disorders.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical applications of anti-CD20 antibodies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid o

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Epstein-barr virus-induced lymphoma in a cardiac transplant recipient

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Orthotopic homotransplantation of the human liver

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of post-transplant lymphomas with anti-B-cell monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21391

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21391

1 reference

Europe PubMed Central

13 August 2017

release_jk2ci6vrq5f3bmhyhzkt3dhhpe

1 reference

https://api.fatcat.wiki/v0/release/jk2ci6vrq5f3bmhyhzkt3dhhpe

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36251995&oldid=2001851138"